Clinical Trial Update: An Open Positron Emission Tomography Study to Assess the Effects of Varying Mass of AZD4694 on Radioligand Binding Parameters in Healthy Volunteers and Patients With Alzheimer's Disease [Phase 1]

View source ↗

Summary

A completed Phase 1 PET study evaluating how varying masses of AZD4694 affect radioligand binding in healthy volunteers and patients with Alzheimer's disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• AZD4694

Snippet

Sponsor: AstraZeneca | Conditions: Maximum Diagnostic Mass of [18Fluor]AZD4694 | Phase 1 | Status: COMPLETED